MicroRNAs (miRNAs) are short, non-coding RNA molecules that have emerged as important regulators of gene expression in humans. Most mature miRNAs are approximately 19–25 nucleotides long and regulate gene expression primarily through interactions with messenger RNA (mRNA). Rather than regulating a single gene, individual miRNAs can influence numerous transcripts and interconnected signaling pathways. This multi-target characteristic allows miRNAs to fine-tune complex biological processes including cell proliferation, differentiation, metabolism, apoptosis, immune responses, and tissue development.

Since the initial discovery of miRNA-mediated gene regulation, research has expanded rapidly, revealing extensive involvement of these molecules in human physiology and disease. Altered miRNA expression has been observed in malignant, cardiovascular, metabolic, neurological, inflammatory, autoimmune, and infectious diseases. Recent research increasingly considers miRNAs not only as intracellular regulatory molecules but also as mediators of communication between different cell types.

The biological importance of miRNAs arises from their ability to regulate networks rather than isolated molecular targets. A single miRNA may simultaneously influence genes involved in inflammation, apoptosis, angiogenesis, oxidative stress, cell-cycle progression, and metabolism. Conversely, a single mRNA can potentially be regulated by multiple miRNAs. This creates a highly interconnected regulatory network that can respond dynamically to physiological and pathological stimuli.

MiRNA expression can be influenced by genetic alterations, epigenetic mechanisms, transcription factors, environmental conditions, inflammation, metabolic changes, and cellular stress. Consequently, disease-associated changes in miRNA expression may reflect both causes and consequences of pathological processes.

An additional characteristic that makes miRNAs clinically attractive is their presence in extracellular biological fluids. Circulating miRNAs can be detected in plasma, serum, urine, saliva, cerebrospinal fluid, and other biological materials. Their relative stability under conditions that degrade many conventional RNA molecules has stimulated considerable interest in their potential as minimally invasive biomarkers. However, recent literature also highlights substantial challenges involving sample preparation, normalization, analytical methods, and validation.

MiRNAs have also attracted attention as therapeutic targets. Two major strategies have emerged: inhibition of disease-promoting miRNAs and restoration of beneficial miRNAs. Antisense oligonucleotides, antagomirs, locked nucleic acids, and miRNA mimics have been investigated in preclinical and clinical settings.

The purpose of this review is to provide an updated overview of the molecular mechanisms of miRNA regulation, their involvement in major human disease pathways, their potential diagnostic and prognostic applications, and the current challenges and opportunities associated with miRNA-based therapies.

2. Biogenesis of MicroRNAs

Transcription of Primary miRNA

Most miRNA genes are transcribed by RNA polymerase II, producing primary miRNA transcripts known as pri-miRNAs. These transcripts can contain characteristic hairpin structures that provide the substrate for subsequent processing.

Pri-miRNAs may be located within independent transcriptional units or embedded within introns or other genomic regions. Their transcription can be regulated by conventional transcription factors, epigenetic modifications, promoter activity, and disease-associated signaling pathways.

Consequently, changes in transcriptional regulation can alter the abundance of mature miRNAs and subsequently influence numerous downstream genes.

Nuclear Processing

The initial processing of pri-miRNA occurs within the nucleus. A microprocessor complex containing Drosha and its partner DGCR8 recognizes the hairpin structure and cleaves the pri-miRNA to produce a precursor miRNA (pre-miRNA).

The resulting pre-miRNA is approximately 60–70 nucleotides long and contains a characteristic stem-loop structure.

Cytoplasmic Processing

Pre-miRNAs are transported from the nucleus to the cytoplasm, where the RNase III enzyme Dicer processes them into short RNA duplexes.

One strand of the duplex is incorporated into the RNA-induced silencing complex (RISC), while the other strand is generally degraded or may sometimes have an independent biological function.

The mature miRNA associates primarily with an Argonaute protein and guides the complex toward complementary sequences within target RNAs.

The canonical biogenesis pathway therefore involves sequential processing by Drosha and Dicer, although alternative and non-canonical pathways have also been identified.

3. Molecular Mechanisms of miRNA-Mediated Gene Regulation

Interaction with Messenger RNA

The most established function of miRNAs is post-transcriptional regulation of gene expression.

The mature miRNA recognizes target sequences through complementary base pairing, particularly involving the seed region located near the 5′ end of the miRNA. Binding frequently occurs within the 3′ untranslated region of target mRNAs.

Depending on the degree of complementarity and cellular context, miRNA binding can result in translational repression, deadenylation, decapping, and degradation of the target mRNA.

Through this mechanism, miRNAs can reduce the production of specific proteins without necessarily eliminating the corresponding gene.

Multi-Target Regulation

One of the most important characteristics of miRNAs is their ability to regulate multiple targets.

For example, a single miRNA may simultaneously influence genes associated with inflammatory signaling, apoptosis, cell-cycle regulation, and metabolism. This characteristic explains why dysregulation of a single miRNA may produce extensive biological consequences.

At the same time, multi-target activity makes therapeutic development challenging because manipulating one miRNA may affect both desired and unintended molecular pathways.

Non-Canonical Functions

Although post-transcriptional repression remains the best-established function of miRNAs, evidence indicates that miRNAs can participate in more complex regulatory mechanisms.

MiRNAs may influence gene expression through interactions with proteins, long non-coding RNAs, circular RNAs, and other components of regulatory networks. Some extracellular miRNAs may also act as signaling molecules between cells.

These observations have expanded the concept of miRNAs from simple intracellular gene silencers to components of complex intercellular regulatory networks.

4. Regulation of MicroRNA Expression

MiRNA expression is controlled at multiple levels.

Transcriptional regulation represents an important mechanism. Transcription factors can bind miRNA promoters and regulate their production. Epigenetic modifications, including DNA methylation and histone modifications, can also influence miRNA expression.

Post-transcriptional regulation occurs during pri-miRNA processing, nuclear export, Dicer processing, and RISC loading.

Environmental and physiological factors can additionally influence miRNA profiles. Hypoxia, oxidative stress, inflammation, infection, nutritional status, hormones, and metabolic alterations have all been associated with changes in miRNA expression.

The complexity of miRNA regulation helps explain why disease-associated miRNA profiles can differ between tissues and disease stages.

5. Role of MicroRNAs in Human Diseases

MicroRNAs and Cancer

Cancer is one of the most extensively studied areas of miRNA research.

MiRNAs can function as either oncogenic or tumor-suppressive regulators depending on the specific miRNA, tissue, and molecular environment. Oncogenic miRNAs, sometimes called oncomiRs, can promote tumor development by suppressing tumor-suppressor genes. Conversely, loss of tumor-suppressive miRNAs can permit abnormal cell proliferation, invasion, angiogenesis, or resistance to apoptosis.

miRNA dysregulation has been documented in breast, lung, colorectal, liver, prostate, pancreatic, and hematological malignancies.

MiR-21 is one of the most frequently studied oncogenic miRNAs and has been associated with pathways regulating apoptosis, proliferation, invasion, and treatment resistance.

The diagnostic potential of circulating miRNAs in cancer has received substantial attention. Recent research has investigated miRNA signatures for early detection of cancers that may otherwise be difficult to identify at an early stage.

However, cancer biomarker development remains challenging because miRNA expression can vary according to tumor subtype, disease stage, ethnicity, sample type, treatment status, and analytical methodology.

6. MicroRNAs in Cardiovascular Diseases

MiRNAs play important roles in cardiovascular development and homeostasis.

They regulate endothelial-cell function, vascular smooth-muscle-cell proliferation, cardiomyocyte growth, apoptosis, fibrosis, inflammation, and angiogenesis.

Dysregulated miRNAs have been associated with coronary artery disease, myocardial infarction, heart failure, hypertension, and cardiac remodeling.

MiR-126, for example, has been associated with vascular endothelial function and angiogenic processes, whereas other miRNAs influence cardiac hypertrophy, fibrosis, and inflammatory responses.

Because miRNAs can regulate multiple genes involved in cardiovascular pathology, they have potential applications in disease diagnosis, prognosis, and treatment.

Recent therapeutic research has investigated both miRNA inhibition and miRNA replacement approaches for cardiovascular disorders. However, efficient tissue-specific delivery remains a major challenge.

7. MicroRNAs in Diabetes and Metabolic Disorders

Metabolic diseases involve complex disturbances in glucose and lipid metabolism, inflammation, insulin signaling, and energy homeostasis.

MiRNAs contribute to these processes by regulating insulin production and signaling, pancreatic β-cell function, adipogenesis, lipid metabolism, hepatic metabolism, and inflammatory pathways.

Recent evidence indicates that miRNA regulatory networks are involved in obesity, diabetes, metabolic dysfunction-associated steatotic liver disease, and alcohol-related liver disease.

For example, miR-122 is strongly associated with hepatic lipid metabolism, while other miRNAs influence insulin sensitivity and inflammatory signaling.

The ability of miRNAs to regulate several metabolic pathways simultaneously makes them attractive candidates for biomarker development. Nevertheless, metabolic diseases are highly heterogeneous, and miRNA signatures may differ between individuals according to age, sex, diet, medication, disease severity, and tissue distribution.

8. MicroRNAs in Neurodegenerative Diseases

The central nervous system has complex miRNA regulatory networks that participate in neuronal differentiation, synaptic function, neuronal survival, and neuroinflammation.

Altered miRNA expression has been observed in Alzheimer's disease, Parkinson's disease, Huntington's disease, and other neurodegenerative disorders.

In Alzheimer's disease, miRNAs may influence amyloid precursor protein processing, amyloid-beta accumulation, tau homeostasis, inflammation, and neuronal survival.

In Parkinson's disease, miRNA dysregulation has been associated with pathways involving neuroinflammation, oxidative stress, protein aggregation, and dopaminergic neuronal survival. Recent reviews have highlighted the potential use of miRNAs as diagnostic biomarkers and therapeutic targets in Parkinson's disease.

Because miRNAs can potentially be measured in blood and cerebrospinal fluid, they may offer opportunities for minimally invasive monitoring of neurological disease. However, the relationship between circulating and brain-specific miRNA expression remains an important research challenge.

9. MicroRNAs in Inflammatory and Autoimmune Diseases

Inflammatory responses depend on tightly regulated interactions between immune cells, cytokines, chemokines, transcription factors, and signaling pathways.

MiRNAs regulate many of these components.

For example, miR-155 is strongly associated with immune activation and inflammatory signaling, while miR-146a has important roles in negative feedback regulation of inflammatory pathways.

Dysregulation of miRNAs has been described in rheumatoid arthritis, inflammatory bowel disease, psoriasis, systemic autoimmune disorders, and other inflammatory conditions.

Recent research emphasizes that miRNAs may have both pro-inflammatory and anti-inflammatory effects depending on their cellular context and target genes.

This context dependence is important when considering miRNAs as therapeutic targets. A miRNA that promotes inflammation in one tissue may perform a protective function in another.

10. MicroRNAs in Infectious Diseases

MiRNAs participate in host responses to bacterial, viral, fungal, and parasitic infections.

During infection, pathogens can alter host miRNA expression, while host miRNAs can influence immune signaling and pathogen replication.

Viral infections have received particular attention because viruses may interact directly with host miRNA pathways or encode their own miRNAs.

Changes in miRNA expression during infection can affect cytokine production, innate immunity, apoptosis, and adaptive immune responses.

A 2023 review highlighted the potential of miRNAs as diagnostic biomarkers and therapeutic targets across viral, bacterial, fungal, and parasitic infections.

These findings suggest that miRNA profiling may eventually contribute to distinguishing infection types, predicting disease severity, or monitoring treatment response.

11. Extracellular and Circulating MicroRNAs

MiRNAs are not restricted to intracellular compartments.

They can be released into extracellular fluids through extracellular vesicles, including exosomes, or associated with proteins and lipoprotein complexes.

Extracellular miRNAs can potentially transfer regulatory information between cells.

For example, a miRNA released by an inflammatory cell may influence gene expression in neighboring cells, thereby contributing to tissue-level responses.

Circulating miRNAs have therefore attracted significant attention as potential biomarkers.

Their relative stability in body fluids is particularly attractive for clinical applications. However, biomarker studies face important technical issues, including sample preparation, RNA extraction, normalization, hemolysis, platform selection, and differences between serum and plasma.

Standardization of these procedures is essential before circulating miRNAs can become routine clinical biomarkers.

12. MicroRNAs as Diagnostic and Prognostic Biomarkers

An effective biomarker should ideally be measurable, reproducible, specific, sensitive, and clinically informative.

MiRNAs have several properties that make them attractive candidates. They are relatively stable in biological fluids, can be detected using molecular techniques, and may display disease-associated expression patterns.

Potential applications include:

• Early disease detection
• Disease classification
• Prognostic assessment
• Monitoring treatment response
• Detection of disease recurrence
• Prediction of therapeutic resistance
• Identification of disease subtypes

Cancer has been a major focus of circulating miRNA biomarker research, including efforts to detect early-stage disease.

Nevertheless, miRNA biomarkers have not yet achieved universal clinical adoption. A major reason is the lack of standardized sample collection, RNA extraction, normalization, and validation procedures. Recent literature specifically identifies these methodological challenges as major barriers to clinical translation.

13. MicroRNA-Based Therapeutic Strategies

Two broad therapeutic strategies have been developed.

miRNA Inhibition

If a miRNA contributes to disease by suppressing beneficial genes, inhibiting that miRNA may restore normal gene expression.

Antisense oligonucleotides, antagomirs, and locked nucleic acid-based inhibitors have been developed for this purpose.

miRNA Replacement

If a beneficial miRNA is reduced during disease, synthetic miRNA mimics can potentially restore its activity.

This approach attempts to reproduce the normal biological function of a tumor-suppressive or protective miRNA.

Delivery Systems

The major challenge in miRNA therapy is efficient and safe delivery.

Potential delivery platforms include:

• Lipid nanoparticles
• Polymer-based nanoparticles
• Extracellular vesicles
• Viral vectors
• Conjugated oligonucleotides

Delivery systems must protect miRNA molecules from degradation, facilitate cellular uptake, and ideally direct the therapeutic molecule toward the affected tissue.

Current reviews indicate that miRNA therapeutics have progressed from experimental studies toward clinical investigation, although significant translational barriers remain.

Review Design

The present study was designed as a narrative review of published scientific literature concerning the molecular biology and disease-related functions of microRNAs.

Literature Search

Relevant literature was identified through searches of PubMed/MEDLINE, major biomedical journals, and other scholarly databases.

The following keywords and combinations were used:

“microRNA,” “miRNA,” “non-coding RNA,” “gene regulation,” “microRNA biogenesis,” “miRNA biomarkers,” “miRNA therapy,” “cancer,” “cardiovascular disease,” “diabetes,” “metabolic disease,” “neurodegenerative disease,” “inflammation,” “autoimmune disease,” and “infectious disease.”

Priority was given to peer-reviewed studies and recent review articles, while important foundational studies were retained to provide appropriate scientific background.

Inclusion Criteria

Literature was included when it:

1. Examined the biological function of miRNAs;
2. Described miRNA biogenesis or gene-regulatory mechanisms;
3. Investigated miRNA involvement in human disease;
4. Evaluated miRNAs as biomarkers;
5. Examined miRNA-based therapeutic strategies; or
6. Provided mechanistic evidence relevant to human disease pathways.

Exclusion Criteria

Articles unrelated to miRNA biology or human disease pathways were excluded. Publications lacking sufficient scientific information or with limited relevance to the objectives of this review were not emphasized.

Data Synthesis

The retrieved literature was organized into five major categories: molecular mechanisms, disease pathways, extracellular miRNAs, biomarker applications, and therapeutic strategies. Findings were synthesized qualitatively to identify established mechanisms, emerging applications, limitations, and future research directions.

15. Results

The reviewed literature demonstrates that miRNAs are central regulators of post-transcriptional gene expression and influence multiple physiological and pathological pathways.

Several major findings emerged.

First, miRNAs regulate gene expression through interactions with target mRNAs and can influence multiple genes simultaneously. This multi-target activity allows miRNAs to coordinate complex biological pathways.

Second, dysregulated miRNA expression is consistently associated with major human diseases, particularly cancer, cardiovascular disorders, metabolic diseases, neurodegenerative conditions, inflammatory disorders, and infections.

Third, miRNAs can participate in intercellular communication through extracellular vesicles and other circulating carriers. This provides a potential mechanism through which disease-associated miRNA signals can spread between cells.

Fourth, circulating miRNAs demonstrate considerable potential as minimally invasive biomarkers. However, methodological differences in collection, extraction, normalization, and detection remain major barriers to clinical standardization.

Fifth, miRNA-based therapies have advanced considerably. Both miRNA inhibition and replacement strategies have entered preclinical and clinical research. Nevertheless, tissue-specific delivery, off-target activity, toxicity, immune responses, and biological heterogeneity remain important limitations.

The accumulated evidence demonstrates that miRNAs represent an important layer of gene regulation between transcription and protein production. Their ability to regulate multiple genes provides a mechanism for coordinating cellular responses to physiological and pathological stimuli.

One of the most significant characteristics of miRNAs is their network-level regulatory capacity. Traditional pharmacological approaches often focus on individual proteins or receptors, whereas a single miRNA can simultaneously regulate several components of a biological pathway. This characteristic may provide therapeutic advantages for multifactorial diseases in which several molecular abnormalities occur simultaneously.

However, the same characteristic also creates challenges. A therapeutic miRNA may influence unintended genes, resulting in off-target effects. Therefore, successful miRNA therapeutics require careful characterization of both intended and unintended targets.

Cancer provides a particularly clear example of the complexity of miRNA regulation. Oncogenic miRNAs can suppress tumor-suppressor pathways, while tumor-suppressive miRNAs can restrict proliferation and survival. The same miRNA may also behave differently in different tumor types depending on its target-gene environment.

In cardiovascular disease, miRNAs regulate endothelial function, inflammation, fibrosis, angiogenesis, and cardiomyocyte survival. Their network effects make them attractive therapeutic candidates, but efficient delivery to specific cardiovascular tissues remains challenging.

Metabolic diseases provide another important example. MiRNAs can regulate glucose and lipid metabolism simultaneously, making them potentially useful targets for complex metabolic disorders. Recent research indicates that miRNA regulatory networks are involved in obesity, diabetes, and metabolic liver disease.

In neurological disorders, miRNA dysregulation may influence neuroinflammation, oxidative stress, protein aggregation, and neuronal survival. Evidence from Parkinson's disease and other neurodegenerative disorders suggests potential diagnostic and therapeutic applications.

The development of circulating miRNA biomarkers is particularly promising. Unlike tissue biopsies, blood-based tests could potentially allow repeated monitoring. However, miRNA measurements can be influenced by hemolysis, sample handling, normalization strategy, and analytical platform. Consequently, large multicenter studies and standardized protocols are necessary before individual miRNA signatures can be adopted clinically.

Therapeutic development is similarly progressing but remains technically demanding. MiRNA mimics and inhibitors must reach the correct cells at appropriate concentrations while avoiding immune activation and unintended effects. Advances in lipid nanoparticles, extracellular vesicles, and other delivery technologies may help overcome these limitations.

Future research should also move beyond studying individual miRNAs. Disease-associated regulatory networks frequently involve multiple interacting miRNAs, mRNAs, long non-coding RNAs, circular RNAs, and transcription factors. Systems biology, artificial intelligence, and multi-omics approaches may therefore provide more accurate models of miRNA-mediated disease mechanisms.

Overall, miRNAs should be considered components of complex regulatory networks rather than isolated biomarkers or therapeutic targets.

17. Future Perspectives

Several areas require further investigation.

First, standardized methodologies are needed for circulating miRNA measurement. Differences in sample preparation and normalization currently make comparison between studies difficult.

Second, future studies should distinguish tissue-specific miRNA changes from systemic changes. A circulating miRNA may originate from multiple tissues and therefore may not directly represent the disease site.

Third, advanced delivery systems should be developed to improve tissue specificity and reduce off-target effects.

Fourth, longitudinal clinical studies are needed to determine whether miRNA changes predict disease development before conventional clinical manifestations become apparent.

Fifth, artificial intelligence and machine-learning algorithms may assist in identifying combinations of miRNAs that provide greater diagnostic accuracy than individual miRNAs. Recent research has already begun combining circulating miRNA biomarkers with biosensors and computational approaches for cancer detection.

Finally, future clinical trials should establish appropriate patient selection criteria, dosing strategies, safety profiles, and long-term effects of miRNA-based therapies.

MicroRNAs represent a major regulatory layer of human gene expression and have important functions in health and disease. Through post-transcriptional regulation of multiple target genes, miRNAs influence cellular proliferation, apoptosis, inflammation, metabolism, immune responses, angiogenesis, and tissue homeostasis.

Dysregulation of miRNA networks contributes to numerous diseases, including cancer, cardiovascular disease, diabetes, metabolic disorders, neurodegenerative diseases, inflammatory conditions, and infectious diseases.

Their stability in biological fluids and disease-associated expression patterns make circulating miRNAs promising candidates for non-invasive diagnostic and prognostic biomarkers. At the same time, miRNA mimics and inhibitory molecules provide potential therapeutic approaches for restoring or suppressing disease-associated regulatory pathways.

Despite these opportunities, important challenges remain, particularly regarding target specificity, delivery, off-target effects, biological variability, and standardization of biomarker assays.

Future integration of miRNA biology with genomics, transcriptomics, proteomics, metabolomics, artificial intelligence, and precision medicine may facilitate the development of clinically useful miRNA-based diagnostic and therapeutic strategies. Continued investigation of miRNA regulatory networks is therefore likely to contribute significantly to the understanding and treatment of complex human diseases.

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi:10.1016/S0092-8674(04)00045-5.
2. Bartel DP. Metazoan MicroRNAs. Cell. 2018;173(1):20–51. doi:10.1016/j.cell.2018.03.006.
3. Ha M, Kim VN. Regulation of microRNA biogenesis. Nature Reviews Molecular Cell Biology. 2014;15:509–524. doi:10.1038/nrm3838.
4. O'Brien J, Hayder H, Peng C. The history, biogenesis and biological activity of RNA-based gene regulation. Journal of Biomedical Science. 2018;25:19.
5. Kimura M, Kothari S, Gohir W, Camargo JF, Husain S. MicroRNAs in infectious diseases: potential diagnostic biomarkers and therapeutic targets. Clinical Microbiology Reviews. 2023;36(4):e00015-23.
6. Metcalf GAD. MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances. Oncogene. 2024;43:2135–2142.
7. Ma N. MicroRNAs in metabolic dysfunction-associated diseases: pathogenesis and therapeutic opportunities. FASEB Journal. 2024;38(17):e70038.
8. Nalbant E, Akkaya-Ulum YZ. Exploring regulatory mechanisms on miRNAs and their implications in inflammation-related diseases. Clinical and Experimental Medicine. 2024;24:142.
9. Brillante S, Volpe M, Indrieri A. Advances in MicroRNA Therapeutics: From Preclinical to Clinical Studies. Human Gene Therapy. 2024;35(17–18). doi:10.1089/hum.2024.113.
10. Zinovkin RA, Sakharov IY. Challenges of using microRNAs as potential disease biomarkers: A review. Microchemical Journal. 2024;206:111379. doi:10.1016/j.microc.2024.111379.
11. Liu Z, Fu Y, Yan M, et al. microRNAs in kidney diseases: Regulation, therapeutics, and biomarker potential. Pharmacology & Therapeutics. 2024;262:108709. doi:10.1016/j.pharmthera.2024.108709.
12. Shaheen N, Shaheen A, Osama M, et al. MicroRNAs regulation in Parkinson's disease, and their potential role as diagnostic and therapeutic targets. npj Parkinson's Disease. 2024;10:186.
13. Zabalza A, Pappolla A, Comabella M, Montalban X, Malhotra S. MiRNA-based therapeutic potential in multiple sclerosis. Frontiers in Immunology. 2024;15:1441733. doi:10.3389/fimmu.2024.1441733.
14. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circulation Research. 2012;110(3):483–495.
15. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469:336–342.
16. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nature Reviews Drug Discovery. 2017;16:203–222.
17. Lu TX, Rothenberg ME. MicroRNA. Journal of Allergy and Clinical Immunology. 2018;141(4):1202–1207.
18. Tüfekci KU, Oner MG, Meuwissen RLJ, Genç S. The role of microRNAs in human diseases. Methods in Molecular Biology. 2014;1107:33–50.
19. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nature Reviews Immunology. 2010;10:111–122.
20. Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nature Reviews Molecular Cell Biology. 2019;20:21–37.
21. MicroRNAs: a symphony orchestrating evolution and disease dynamics. Trends in Molecular Medicine. 2025;31(1):21–35. doi:10.1016/j.molmed.2024.07.004.
22. The role of microRNA in the development, diagnosis, and treatment of cardiovascular disease: Recent developments. Journal of Pharmacology and Experimental Therapeutics. 2023;384(1):123–132.
23. MicroRNAs: Key modulators of inflammation-associated diseases. Seminars in Cell & Developmental Biology. 2024;154:364–373. doi:10.1016/j.semcdb.2023.01.009.
24. The role of microRNAs in the pathophysiology of human central nervous system: A focus on neurodegenerative diseases. Ageing Research Reviews. 2023;92:102090. doi:10.1016/j.arr.2023.102090.
25. Pharmacological and molecular mechanisms of miRNA-based therapies for targeting cardiovascular dysfunction. Biochemical Pharmacology. 2024;228:116318.